FGFR Inhibitor Shows Preclinical Activity in Breast Cancer
This video highlights preclinical activity of a novel FGFR inhibitor that has been tested alone and in combination with antihormonal therapy in breast cancer cell lines.
In this video, Dominik Mumberg, PhD, of Bayer AG in Berlin, highlights preclinical activity of a novel FGFR inhibitor that has been tested alone and in combination with antihormonal therapy in breast cancer cell lines.
The data were presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.
Recent Videos
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
